ArticleGeroScience2025
Self-testing for symptoms and signs of prodromal alpha-synucleinopathies: results from the Tasmanian ISLAND Sleep Study.
Article in GeroScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Isolated rapid eye movement (REM) sleep behavior disorder (iRBD) may occur at least 10 years before a clinical diagnosis of an α-synucleinopathy, such as dementia with Lewy bodies (DLB), Parkinson's disease (PD) or multiple system atrophy (MSA). The extent to which people with iRBD manifest subtle features of these conditions is an area of active research and whether these changes can be measured remotely in the community is an important aim. Better characterisation may aid early detection and monitoring for people at risk of neurodegeneration. The aim of this study was to investigate remote tests of subjective and objective features of α-synuclein-related conditions in probable iRBD (pRBD). We hypothesised that α-synuclein-related symptoms and signs would be more frequent in pRBD than healthy controls. 2,891 participants aged 50 + from the Tasmanian ISLAND Sleep Study completed the REM Sleep Behavior Disorder Single-Question Screen (RBD1Q), and several online questionnaires and unsupervised objective assessments of motor, cognitive and olfactory function. People with pRBD (n = 267; mean (SD) age 63 (7.6) years; 53% female) reported more α-synuclein-related features than controls (n = 2,624; mean (SD) age 64 (7.7) years; 75% female), especially orthostatic intolerance, neuropathic pain, falls, olfactory impairment and hand motor dysfunction. These results show that people with pRBD exhibit a range of symptoms and signs of α-synuclein-related conditions that can be measured using remote (online and postal) assessment tools. Remote monitoring in the community may aid early detection of progression to DLB, PD and MSA and facilitate enrolment into clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.